Abstract
The present disclosure provides methods for using fitusiran to treat hemophilia A in patients who have previously been treated with emicizumab.
Full Text
What is claimed is:
The present disclosure provides methods for using fitusiran to treat hemophilia A in patients who have previously been treated with emicizumab.
Timeline
Filed
03/12/2026Published
07/02/2026Granted
Not AvailableIPC Codes(5)
C12N 15/113:Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 38/37:Factors VIII
A61K 38/48:acting on peptide bonds (3.4)